Bioasis is dedicated to delivering hope to patients suffering with neurological diseases and disorders. Our breakthrough science focuses on transporting medicines across the blood-brain barrier, providing a path to hundreds of previously untreatable diseases of the central nervous system.
1 in 6 People Worldwide
Neurological disease affects 1.25 billion people worldwide, and the incidence of these disorders is only increasing. Bioasis is determined to deliver effective treatments to patients suffering with these diseases.
Our Science
A Barrier to Better Health
The blood-brain barrier plays an essential role in protecting the brain from blood-borne disease. However, it also blocks otherwise effective medicine from reaching the brain. Most drugs created to treat central nervous system diseases and disorders fail because they aren't optimally designed to be delivered in sufficient quantities to the brain.
Blood-Brain Barrier
Latest News
Bioasis Technologies Inc. Announces Stock Option GrantsAug. 8, 2022
NEW HAVEN, Conn., Aug. 08, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company...
Bioasis Announces Filing of Its First Quarter Financial Statements and MD&AJul. 29, 2022
NEW HAVEN, Conn., July 29, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC.?(TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary...
Bioasis Acquires Phase 2 Ready Rare Orphan EGF AssetsJun. 16, 2022
Phase 2 ready assets transform Bioasis into a clinical stage company with a multi-asset pipeline focused on rare and orphan drug indications Unique approach to neurodegeneration targeting...
Transporting Treatment
The Bioasis xB3 platform provides researchers with a path for the delivery of treatments across the blood-brain barrier and into the brain. Our technology offers a solution to a problem that for decades has blocked development of effective treatment of neurological disorders.
Our Platform